MoonLake Immunotherapeutics (MLTX) Long-Term Investments (2020 - 2022)

MoonLake Immunotherapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $115.1 million for Q1 2022.

• In Q1 2022, Long-Term Investments rose 12712721.99% year-over-year to $115.1 million; the TTM figure through Mar 2022 stood at $115.1 million (up 12712721.99% YoY), while the FY2021 annual figure was $115.0 million, up 25173337.2% from the prior year.
• Long-Term Investments for Q1 2022 stood at $115.1 million, roughly flat from $115.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $115.1 million in Q1 2022, with the low at $457.0 in Q4 2020.
• The 3-year median for Long-Term Investments is $115.0 million (2021), against an average of $76.7 million.
• The sharpest annual moves came in 2021 and 2022: Long-Term Investments soared 25173337.2% in 2021, then surged 12712721.99% in 2022.
• MoonLake Immunotherapeutics' Long-Term Investments stood at $457.0 in 2020, then jumped by 25173337.2% to $115.0 million in 2021, then increased by 0.01% to $115.1 million in 2022.
• Business Quant data shows MLTX's Long-Term Investments at $115.1 million in Q1 2022, $115.0 million in Q4 2021, and $115.0 million in Q3 2021.